Frank Vocci, Ph.D., Becomes Third Co-Editor of JAM

Frank Vocci, Ph.D.

Frank Vocci, Ph.D.

ASAM’s Board of Directors voted during the Med-Sci Conference to approve the selection of Frank Vocci, Ph.D., as the third Co-Editor for Journal of Addiction Medicine (JAM), ASAM’s official journal. The addition of Dr. Vocci comes at a critical moment in the journal’s progress and in the wake of several successes in solidifying JAM as a leading scientific journal in addiction medicine.

That’s the word conveyed by JAM Senior Editor George F. Koob, Ph.D., and Co-Editors Martha J. Wunsch, M.D., FAAP, FASAM, and Shannon C. Miller, M.D., FASAM, FAPA. Since its creation five years ago, the journal has expanded the scope of its operation and been included in PubMed, an endorsement that is considered rapid among medical journals and denotes the publication as a significant medical journal with a society base that publishes on time and fills its pages with content that is frequently cited.

“This indexing will enable JAM to finally compete on a more level playing field with other medical journals and compete for citations,” Dr. Miller says. “We have managed to increase both our impact factor and rejection rate, all without PubMed citation. PubMed citation will now provide a paradigm shift in visibility for articles published in JAM, improving our opportunity to be cited by other journals.”

Bringing Dr. Vocci on board as a Co-Editor is the next step in the journal’s progression. “Outside of his prominence in the field of addiction medicine, we are excited to have a leader with vast expertise in clinical trials,” Dr. Miller says. “His addition will help strengthen our research in clinical trials, which is key to improving the quality of addiction care.”

Dr. Vocci is President and the Senior Research Scientist at the Friends Research Institute. He earned a doctorate in neuropharmacology, has completed a fellowship in addiction pharmacology, and worked for more than 10 years at the Food and Drug Administration reviewing analgesic medications and medication treatments for addiction disorders in addition to directing the National Institute of Drug Abuse’s medications development program for 13 years.

The editors of JAM attribute the journal’s success to strong ASAM backing, a creative team effort among the editors—Drs. Koob, Wunsch, and Miller—and a small cadre of dedicated support staff.

JAM supports the mission of ASAM by helping to focus attention on addiction problems, an attention that Drs. Miller and Wunsch say has waxed and waned since ASAM was created in 1954. Lately, that attention has been on the rise, with the public showing more understanding of addiction as a disease. JAM will continue to emphasize alcohol and drug addiction, but other aspects of addiction and addiction-related conditions also receive attention in JAM, the co-editors say.

“Addiction has been around for a long time, obviously, but JAM‘s ability to flourish signals recognition of the importance of clinical research by our medical brethren,” Dr. Wunsch says.

JAM publisher Lippincott Williams & Wilkins and ASAM have agreed to support the editors’ request for more pages—pushing the number of issues from four to six per year—and the recent addition of electronic publication ahead of print. The addition of Dr. Vocci as the third Co-Editor rounds out the advances the journal has made over the past years.

All this will occur between now and 2014 and “will enable the journal to reach out to more authors,” Dr. Wunsch says. The journal has already received “an increased number of submissions and has an increasing impact factor in the past two years, at a time when most journals have held steady or seen a reduction in impact factor.” Later this year, JAM plans to supplement its core content with a separate section devoted to coverage of ASAM-generated content of high interest to ASAM members.

The editors invite all to visit JAM online at www.journaladdictionmedicine.com, and encourage authors to submit research for publication by visiting www.editorialmanager.com/JAM.